Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

@inproceedings{Kishiki2014OverexpressionOM,
  title={Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS},
  author={Tomokazu Kishiki and Hiroaki Ohnishi and Tadahiko Masaki and Kouki Ohtsuka and Y. Ohkura and Jyunji Furuse and Takashi Watanabe and Masanori Sugiyama},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2014}
}
Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are actively being sought. We retrospectively evaluated the efficacy of anti-EGFR MoAb-based therapies in 91 patients with mCRC according to KRAS, BRAF, and PIK3CA mutational status as well as PTEN and MET expression. In the patient group with wild-type KRAS, the… CONTINUE READING
Highly Cited
This paper has 70 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

71 Citations

05020142015201620172018
Citations per Year
Semantic Scholar estimates that this publication has 71 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Is there a role for IgF1r and c-Met pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer

  • Inno a, M DiSalvatore, Cenci t, M Martini, Orlandi a, Strippoli a
  • 2011
Highly Influential
4 Excerpts

Combined analysis of KraS and PIK3Ca mutations, Met and Pten expression in primary tumors and corresponding metastases in colorectal cancer

  • Voutsina a, M tzardi, Kalikaki a, Z Zafeiriou, Papadimitraki e, M Papadakis
  • Mod Pathol
  • 2012
3 Excerpts

Hasina r, gangadhar t, Salgia r (2011) the role of the c-met pathway in lung cancer and the potential for targeted therapy

  • M Sattler, MM reddy
  • ther adv Med Oncol
  • 2011
1 Excerpt

Is there a role for IgF 1 r and c - Met pathways in resistance to cetuximab in metastatic colorectal cancer ?

  • M DiSalvatore, Cenci t, M Martini, Orlandi a, Strippoli a
  • Clin Colorectal Cancer
  • 2011

Similar Papers

Loading similar papers…